HVB MINI FUTURE BULL - ASTRAZENECA | Market Closed - Börse Stuttgart 19:54:14 06/05/2024 BST | ||
| 5.3 EUR | -0.93% |
|
| Current month | -0.56% | ||
| 1 month | +43.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 5.3 | -0.93% | 0 |
| 03/05/24 | 5.35 | -2.01% | 0 |
| 02/05/24 | 5.46 | +2.44% | 0 |
| 30/04/24 | 5.33 | +0.19% | 0 |
| 29/04/24 | 5.32 | -0.56% | 0 |
Delayed Quote Börse Stuttgart
Last update May 06, 2024 at 07:54 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6WGF |
| ISIN | DE000HR6WGF8 |
| Date issued | 16/04/2021 |
| Strike | 7,459 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6 € |
|---|---|
| Lowest since issue | 0.8 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
163.6
USD
Spread / Average Target
+8.19%
- Stock Market
- Certificates
- Certificat
